Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Rebecca M Nisbet"'
Autor:
Rinie Bajracharya, David Brici, Liviu-Gabriel Bodea, Phillip W. Janowicz, Jürgen Götz, Rebecca M. Nisbet
Publikováno v:
Acta Neuropathologica Communications, Vol 9, Iss 1, Pp 1-13 (2021)
Abstract One of the main pathological hallmarks of Alzheimer’s disease (AD) is the intraneuronal accumulation of hyperphosphorylated tau. Passive immunotherapy is a promising strategy for the treatment of AD and there are currently a number of tau-
Externí odkaz:
https://doaj.org/article/4286f9b494104bcda22c0c56c8102b26
Publikováno v:
Journal of Huntington's Disease. 12:1-13
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder. The disease, characterized by motor, cognitive, and psychiatric impairments, is caused by the expansion of a CAG repeat in the huntingtin gene. Despite the discovery of
Autor:
Soumya Mukherjee, Celine Dubois, Keyla Perez, Shiji Varghese, Ian E. Birchall, Miranda Leckey, Natalia Davydova, Catriona McLean, Rebecca M. Nisbet, Blaine R. Roberts, Qiao‐Xin Li, Colin L. Masters, Victor A. Streltsov
Publikováno v:
Journal of Neurochemistry. 164:529-552
The two hallmarks of Alzheimer's disease (AD) are amyloid-β (Aβ) plaques and neurofibrillary tangles marked by phosphorylated tau. Increasing evidence suggests that aggregating Aβ drives tau accumulation, a process that involves synaptic degenerat
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2014 (2021)
For the treatment of neurological diseases, achieving sufficient exposure to the brain parenchyma is a critical determinant of drug efficacy. The blood–brain barrier (BBB) functions to tightly control the passage of substances between the bloodstre
Externí odkaz:
https://doaj.org/article/30e8daac6a104f16affd2ef28b4a818e
Publikováno v:
Journal of Controlled Release. 349:634-648
Tau-specific immunotherapy is an attractive therapeutic strategy for the treatment of Alzheimer’s disease and other tauopathies. However, targeting tau effectively remains a considerable challenge due to the restrictive nature of the blood-brain ba
Autor:
Joanna M. Wasielewska, Juliana C. S. Chaves, Rebecca L. Johnston, Laura A. Milton, Damián Hernández, Liyu Chen, Jae Song, Wendy Lee, Gerhard Leinenga, Rebecca M. Nisbet, Alice Pébay, Jürgen Götz, Anthony R. White, Lotta E. Oikari
Publikováno v:
Theranostics. 12:6826-6847
RationaleThe blood-brain barrier (BBB) is a major impediment to therapeutic intracranial drug delivery for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). Focused ultrasound applied together with microbubbles (FUS+M
Autor:
Rebecca M. Nisbet
Publikováno v:
Science. 379:1300-1301
Neuronal clearance of proteins in the brain proves to be important for immunotherapy
Autor:
Victor A Streltsov, Shiji Varghese, Soumya Mukherjee, Liang Jin, Catriona McLean, Blaine R. Roberts, Ian Birchall, Celine Dubois, Colin L. Masters, Qiao-Xin Li, Kevin J Barham, Rebecca M Nisbet, Laura J Vella, Keyla Perez
Publikováno v:
ACS Chemical Neuroscience. 12:3719-3732
Protein citrullination (deimination of arginine residue) is a well-known biomarker of inflammation. Elevated protein citrullination has been shown to colocalize with extracellular amyloid plaques in postmortem AD patient brains. Amyloid-β (Aβ) pept
Autor:
Soumya Mukherjee, Celine Dubois, Keyla Perez, Rebecca M Nisbet, Qiao‐Xin Li, Shiji Varghese, Larissa Cristina Lago, Stephan Klatt, Ian Birchall, Liang Jin, Catriona McLean, Victor Streltsov, Kevin J Barnham, Laura J Vella, Colin L Masters
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Rebecca M. Nisbet, David Brici, Rinie Bajracharya, Phillip W. Janowicz, Liviu-Gabriel Bodea, Jürgen Götz
Publikováno v:
Acta Neuropathologica Communications, Vol 9, Iss 1, Pp 1-13 (2021)
Acta Neuropathologica Communications
Acta Neuropathologica Communications
One of the main pathological hallmarks of Alzheimer’s disease (AD) is the intraneuronal accumulation of hyperphosphorylated tau. Passive immunotherapy is a promising strategy for the treatment of AD and there are currently a number of tau-specific